|
Formulation development and evaluation of sustained release bilayer tablet containing pioglitazone and glucosum in management of hypoglycemic diabetes.
|
|
| Author:
|
VINAYAK MADANE, SANTOSH FATTEPUR, SHRUTI SONAWANE, AMIT KASABE, NAGARAJA SREEHARSHA
|
| Abstract:
|
Increasingly, pharmaceutical invention and research are focusing on delivery systems that improve desirable therapeutic objectives while minimising side effects. Nowadays there are very few medicines coming out of research and development and already existing drugs are facing resistance issues because of their irrational use of drugs such as antibiotics. Bilayered tablets for effective use in the treatment of hypoglycaemia, i.e. low blood glucose or low blood sugar, will be developed and tested in this study. Hypoglycaemia is one of the well-known drawbacks associated with most antidiabetic agents used in the administration of type 2 diabetes mellitus. So it needs to be overcome or handled quickly, if left untreated, may escalate and cause confusion, torment or fainting and may lead to convulsions, coma, and even death. So, to overcome above problem, bilayer tablet containing Pioglitazone and Glucosum is formulated. Pioglitazone is a hyperglycaemic ant used for the treatment of type II diabetes mellitus, whereas; Glucosum is one of a group of -carbohydrates called single sugars. The bilayer tablet includes pioglitazone and glucosum along with the use of various grade polymers, namely HPMC. K35 M, K4 M AND E10 M and other excipients have been found to be consistent with different concentrations of polymers. The results of the pre- and post-compression parameters were verified according to USP guidelines. In vitro drug release for F1 to F18 formulation were found to follow peppas model for drug release.
|
| Keyword:
|
Sustained release bilayer tablet, Pioglitazone, Glucosum, hypoglycaemia.
|
| EOI:
|
-
|
| DOI:
|
https://doi.org/10.31838/ijpr/2020.SP2.539
|
| Download:
|
Request For Article
|
|
|